enGene Therapeutics details CBO stock options

Q: What role does Chinoporos Constantine hold at enGene Therapeutics (ENGN)?

Chinoporos Constantine serves as enGene Therapeutics’ Interim Chief Business Officer. This officer role is disclosed alongside his reported stock option position, highlighting his executive status within the company’s leadership team.

Q: How many ENGN shares are covered by Chinoporos Constantine's reported options?

The reported position covers stock options on 75,000 common shares of enGene Therapeutics. These options provide a right to buy the company’s common shares under the terms and schedule described in the disclosure.

Q: What is the exercise price and expiration date of the ENGN options held by Chinoporos Constantine?

The options have an exercise price of $1.7500 per share and an expiration date of 2036-06-16. This defines the cost to acquire each underlying common share and the last date the option can be exercised.

Q: Are Chinoporos Constantine's ENGN options held directly or indirectly?

The reported stock option position is held directly by Chinoporos Constantine. The ownership type is coded as direct, indicating it is not held through an intermediary entity such as a trust or partnership.

Q: What type of security is reported for Chinoporos Constantine in ENGN's insider filing?

The security reported is a Stock Option (Right to Buy) with an underlying security of Common Shares. This gives the holder the right to purchase enGene Therapeutics common shares under the specified terms.

enGene Therapeutics Inc. reports that Interim Chief Business Officer Chinoporos Constantine holds a stock option covering 75,000 common shares.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

enGene Therapeutics Inc. reports that Interim Chief Business Officer Chinoporos Constantine holds a stock option covering 75,000 common shares. The option has an exercise price of $1.7500 per share, expires on 2036-06-16, and vests monthly in substantially equal amounts over 48 months commencing June 16, 2026, subject to continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Chinoporos Constantine

Role Interim Chief Business Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy) ^F1	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 75,000 contracts (Direct)

Footnotes (1)

F1. This option vests monthly in substantially equal amounts for 48 months, commencing June 16, 2026, subject to the Reporting Person's continued service.

Key Figures

Underlying option shares: 75,000.0000 shares Exercise price: $1.7500 per share Option expiration: 2036-06-16 +2 more

5 metrics

Underlying option shares 75,000.0000 shares Stock Option (Right to Buy) over common shares

Exercise price $1.7500 per share Exercise price for the reported stock option

Option expiration 2036-06-16 Expiration date of the stock option position

Vesting period 48 months Vests monthly in substantially equal amounts commencing June 16, 2026

Vesting commencement date June 16, 2026 Vesting requires the reporting person’s continued service

Key Terms

Stock Option (Right to Buy), underlying security, exercise price, vests monthly

4 terms

Stock Option (Right to Buy) financial

"Security title is Stock Option (Right to Buy) over common shares"

underlying security financial

"The underlying security title is Common Shares"

exercise price financial

"The exercise price is $1.7500 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests monthly financial

"This option vests monthly in substantially equal amounts for 48 months"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What role does Chinoporos Constantine hold at enGene Therapeutics (ENGN)?

Chinoporos Constantine serves as enGene Therapeutics’ Interim Chief Business Officer. This officer role is disclosed alongside his reported stock option position, highlighting his executive status within the company’s leadership team.

How many ENGN shares are covered by Chinoporos Constantine's reported options?

The reported position covers stock options on 75,000 common shares of enGene Therapeutics. These options provide a right to buy the company’s common shares under the terms and schedule described in the disclosure.

What is the exercise price and expiration date of the ENGN options held by Chinoporos Constantine?

The options have an exercise price of $1.7500 per share and an expiration date of 2036-06-16. This defines the cost to acquire each underlying common share and the last date the option can be exercised.

What is the vesting schedule for Chinoporos Constantine's ENGN stock options?

The option vests monthly in substantially equal amounts over 48 months, commencing June 16, 2026. Vesting is subject to the reporting person’s continued service, meaning ongoing service is required for future vesting.

Are Chinoporos Constantine's ENGN options held directly or indirectly?

The reported stock option position is held directly by Chinoporos Constantine. The ownership type is coded as direct, indicating it is not held through an intermediary entity such as a trust or partnership.

What type of security is reported for Chinoporos Constantine in ENGN's insider filing?

The security reported is a Stock Option (Right to Buy) with an underlying security of Common Shares. This gives the holder the right to purchase enGene Therapeutics common shares under the specified terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/22/2026 - 04:05 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Chinoporos Constantine

(Last)

(First)

(Middle)

C/O 4868 RUE LEVY, SUITE 220

(Street)

SAINT-LAURENT

H4R 2P1

(City)

(State)

(Zip)

QUEBEC, CANADA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/16/2026

3. Issuer Name and Ticker or Trading Symbol
enGene Therapeutics Inc. [ ENGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Interim Chief Business Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	06/16/2036	Common Shares	75,000	$1.75	D

Explanation of Responses:

1. This option vests monthly in substantially equal amounts for 48 months, commencing June 16, 2026, subject to the Reporting Person's continued service.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Kathleen P. Richton, as attorney-in-fact for the Reporting Person	07/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR